Wall Street Increases Loss Estimates for Exact Sciences Following Details of Clinical Trial Plans

While a number of analysts maintained prior ratings on Exact Sciences, Rodman & Renshaw downgraded the company to Perform from Outperform.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories